Holen Sie sich die Stockscreener-App
2.96
6.33%
-0.20
Schlusskurs vom Vortag:
$3.16
Offen:
$3.16
24-Stunden-Volumen:
1.20M
Relative Volume:
0.95
Marktkapitalisierung:
$213.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-292.19M
KGV:
-0.652
EPS:
-4.54
Netto-Cashflow:
$-208.41M
1W Leistung:
-20.86%
1M Leistung:
+114.49%
6M Leistung:
+112.95%
1J Leistung:
+23.85%
1-Tages-Spanne:
$2.9325
$3.25
1-Wochen-Bereich:
$2.9325
$3.95
52-Wochen-Spanne:
$1.01
$3.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Firmenname
Zentalis Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 263-4333
Adresse
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Vergleichen Sie ZNTL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
2.96 | 228.31M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-12 | Hochstufung | Wedbush | Underperform → Neutral |
| 2024-06-20 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-06-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Herabstufung | Wedbush | Neutral → Underperform |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Eingeleitet | Cowen | Outperform |
| 2022-04-06 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-29 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-01-20 | Eingeleitet | Wedbush | Outperform |
| 2020-09-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-28 | Eingeleitet | Guggenheim | Buy |
| 2020-04-28 | Eingeleitet | Jefferies | Buy |
| 2020-04-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update - Defense World
Dow Update: How Zentalis Pharmaceuticals Inc stock reacts to job market data2025 Technical Patterns & Verified Swing Trading Watchlist - Bộ Nội Vụ
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
After-Hours Rally: Zentalis, LifeMD, And NanoViricides Among Top Gainers - Nasdaq
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Progress And Insider Buying - Yahoo Finance
Zentalis Pharma Advances Stir Market as Azenosertib Program Strengthens - timothysykes.com
Zentalis outlines 2026 milestones for azenosertib program - The Globe and Mail
Zentalis Pharmaceuticals Surges After Promising Azenosertib Developments - StocksToTrade
Trade Recap: Will Zentalis Pharmaceuticals Inc stock outperform tech sector in 20252025 Performance Recap & Long-Term Safe Investment Plans - Bộ Nội Vụ
Zentalis Pharmaceuticals Surges with Azenosertib Developments - timothysykes.com
Zentalis Pharmaceuticals, Inc. Provides Corporate Update on Azenosertib Development - TradingView — Track All Markets
Azenosertib plans at Zentalis (NASDAQ: ZNTL) with cash runway to 2027 - Stock Titan
Zentalis Pharmaceuticals Stock (ZNTL) Opinions on Azenosertib Development Update - Quiver Quantitative
Aug Weekly: Is Zentalis Pharmaceuticals Inc. stock ready for breakoutPortfolio Update Summary & Trade Opportunity Analysis Reports - ulpravda.ru
Major Investor Makes Bold Move on Zentalis Pharmaceuticals Stock - TipRanks
Is Zentalis Pharmaceuticals Inc. stock ready for breakoutGap Up & Low Risk Profit Maximizing Plans - Улправда
Insider Buying: Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Purchases 6,459,973 Shares of Stock - MarketBeat
Walters group buys Zentalis Pharmaceuticals (ZNTL) shares for $7.7m By Investing.com - Investing.com Nigeria
Walters group buys Zentalis Pharmaceuticals (ZNTL) shares for $7.7m - Investing.com
Is Zentalis Pharmaceuticals Inc. stock a top pick in earnings seasonWeekly Stock Report & Real-Time Volume Triggers - Улправда
Price Action: Will Zentalis Pharmaceuticals Inc. stock maintain momentum in 2025Quarterly Market Summary & Risk Adjusted Buy/Sell Alerts - Улправда
Will Zentalis Pharmaceuticals Inc. stock outperform tech sector in 2025Trade Risk Assessment & Risk Adjusted Buy and Sell Alerts - Улправда
Why analysts remain bullish on Zentalis Pharmaceuticals Inc. stockOil Prices & Risk Managed Investment Strategies - Улправда
Following a 13% decline over last year, recent gains may please Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional owners - Yahoo Finance
Zentalis Pharmaceuticals: Balancing DENALI Momentum and ASPENOVA Visibility Against Pivotal Data and Execution Risk (Hold Rating Maintained) - TipRanks
Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Shares Bounce 28% But Its Business Still Trails The Industry - simplywall.st
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Zentalis Eyes A Pivotal 2026 As Azenosertib Advances Toward Potential Accelerated Approval - Nasdaq
ZNTL Pharmaceuticals Updates on Azenosertib Development - GuruFocus
What drives Zentalis Pharmaceuticals Inc stock priceGap Fill Strategies & Double Or Triple Capital - earlytimes.in
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 - MarketScreener
Zentalis Pharmaceuticals Provides Corporate Update and - GlobeNewswire
An oral, chemo-free option for hard-to-treat ovarian cancer advances - Stock Titan
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of “Hold” by Brokerages - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Will Zentalis Pharmaceuticals Inc. stock outperform growth indexes2025 Price Action Summary & Verified Swing Trading Watchlists - Улправда
Will Zentalis Pharmaceuticals Inc. stock maintain momentum in 2025Weekly Profit Recap & Free Growth Oriented Trading Recommendations - Bölüm Sonu Canavarı
Will Zentalis Pharmaceuticals Inc. stock see PE expansionWeekly Risk Report & AI Powered Buy/Sell Recommendations - DonanımHaber
Why Zentalis Pharmaceuticals Inc. stock is favored by top institutions2025 Key Highlights & Consistent Income Trade Ideas - Улправда
Zentalis Pharmaceuticals Earnings Notes - Trefis
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Matrix Capital Management Comp Sells 7,500,000 Shares of Stock - Defense World
Insider Selling: Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Sells 7,500,000 Shares of Stock - MarketBeat
Zentalis Pharmaceuticals (ZNTL) director reports 7,500,000 share sale - Stock Titan
[8-K] Zentalis Pharmaceuticals, Inc. Reports Material Event | ZNTL SEC FilingForm 8-K - Stock Titan
Oppenheimer cuts Zentalis stock target to $10, maintains rating - MSN
Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market - Seeking Alpha
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Zentalis Pharma (ZNTL) Stock Analysis Report | Financials & Insights - Benzinga
Can Zentalis Pharmaceuticals Inc. stock surprise with earnings upside2025 Volume Leaders & Reliable Entry Point Alerts - Newser
An analyst sees good growth prospects for Zentalis Pharmaceuticals Inc (ZNTL) - setenews.com
Finanzdaten der Zentalis Pharmaceuticals Inc-Aktie (ZNTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zentalis Pharmaceuticals Inc-Aktie (ZNTL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Matrix Capital Management Comp | 10% Owner |
Dec 15 '25 |
Sale |
1.33 |
7,500,000 |
9,975,000 |
6,459,973 |
| Myers Scott Dunseth | Director |
Apr 30 '25 |
Buy |
1.40 |
21,000 |
29,373 |
281,192 |
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
4.73%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):